Levodopa/Benserazid Devatis (Benserazide, Levodopa)

Levodopa is a precursor that crosses the blood‑brain barrier and is converted into dopamine, directly replenishing the neurotransmitter that is deficient in Parkinson's disease. Benserazide blocks the peripheral conversion of levodopa, ensuring more of the drug reaches the brain where it can be converted to dopamine.

The specific dose of Levodopa/Benserazide Devatis is determined by the prescribing clinician based on the individual patient's disease stage, response to therapy, and tolerability. Only a qualified healthcare professional should set the dosing regimen.

Safety data for Levodopa/Benserazide in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Use during pregnancy or while breastfeeding should only occur if the potential benefits outweigh the potential risks, as assessed by a healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levodopa/Benserazide is considered the most effective oral therapy for symptomatic control of Parkinson's disease because it directly replaces dopamine. Other classes, such as dopamine agonists or MAO‑B inhibitors, may be used as adjuncts or in early disease, but they generally provide less robust motor improvement compared with levodopa‑based regimens.

Levodopa/Benserazide Devatis should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct sunlight to maintain stability and potency throughout its shelf life.

Levodopa/Benserazide Devatis is taken orally, usually with a glass of water. It may be administered with or without food, but consistent timing relative to meals can help reduce gastrointestinal side effects. Patients should follow the dosing schedule prescribed by their clinician.

Serious risks include the development of dyskinesias (involuntary movements), severe orthostatic hypotension, psychiatric disturbances such as hallucinations or psychosis, and rare but life‑threatening conditions like neuroleptic malignant‑like syndrome. Patients should be monitored regularly for these events.

Levodopa/Benserazide Devatis is contraindicated in patients with known hypersensitivity to levodopa, benserazide, or any excipients in the formulation. It should also be avoided in individuals taking non‑selective MAO inhibitors due to the risk of hypertensive crisis, and in patients with narrow‑angle glaucoma.